US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc (ARQT) ニュース

ARQT

Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ARQT

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/04	05 : 00	GlobeNewswire Inc.	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/04/30	05 : 00	GlobeNewswire Inc.	Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/04/10	21 : 00	GlobeNewswire Inc.	Arcutis Appoints David Topper as Chief Financial Officer	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/04/06	05 : 00	GlobeNewswire Inc.	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/04/01	20 : 00	GlobeNewswire Inc.	Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/28	21 : 00	GlobeNewswire Inc.	Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/11	21 : 00	GlobeNewswire Inc.	Arcutis Promotes Todd Tucker to Chief Human Resources Officer	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/11	05 : 00	GlobeNewswire Inc.	Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/10	06 : 00	GlobeNewswire Inc.	New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/07	07 : 14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/07	07 : 09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/07	07 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/06	06 : 00	GlobeNewswire Inc.	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	07 : 47	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	07 : 42	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	07 : 40	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	06 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	06 : 00	GlobeNewswire Inc.	Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/04	22 : 00	GlobeNewswire Inc.	Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/02	06 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/02	06 : 06	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/01	07 : 00	GlobeNewswire Inc.	Arcutis to Present at the TD Cowen 44th Annual Health Care Conference	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/29	13 : 30	GlobeNewswire Inc.	Arcutis Announces Pricing of $150 Million Public Offering	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/29	06 : 54	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/29	06 : 21	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/29	06 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/29	06 : 10	GlobeNewswire Inc.	Arcutis Announces Proposed Public Offering	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/29	06 : 00	GlobeNewswire Inc.	Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/28	06 : 34	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/27	21 : 48	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ARQT	Arcutis Biotherapeutics Inc

Showing the most relevant articles for your search:NASDAQ:ARQT

1 2 3 4 5 6 7 8 9 10 次へ >>

Energy Select Sector SPDR

Financial Select Sector

Invesco QQQ Trust Series 1

Deutsche Telekom (QX)

Verizon Communications

US Dollar vs Euro

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約